Congestive heart failure with preserved EF pharmacotherapy: Revision history

22 June 2022

• curprev 20:1120:11, 22 June 2022‎ Edzelco talk contribs‎ 27,712 bytes +13,587‎ →‎Heart failure preserved ejection fraction (HFpEF)

26 March 2022

• curprev 06:0906:09, 26 March 2022‎ Sara Zand talk contribs‎ 14,125 bytes +4‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 06:0706:07, 26 March 2022‎ Sara Zand talk contribs‎ 14,121 bytes +15‎ No edit summary

12 March 2022

• curprev 13:0813:08, 12 March 2022‎ Sara Zand talk contribs‎ 14,106 bytes +1‎ →‎Overview

2 March 2022

• curprev 14:1314:13, 2 March 2022‎ Sara Zand talk contribs‎ 14,105 bytes +724‎ →‎Overview

1 March 2022

• curprev 10:2810:28, 1 March 2022‎ Sara Zand talk contribs‎ 13,381 bytes +2‎ →‎Mineralocorticoid receptor antagonists
• curprev 10:2810:28, 1 March 2022‎ Sara Zand talk contribs‎ 13,379 bytes +571‎ →‎Beta-blockers
• curprev 10:2310:23, 1 March 2022‎ Sara Zand talk contribs‎ 12,808 bytes +460‎ →‎Heart failure mildly reduced ejection fraction (HPmrEF), EF (41-49%)
• curprev 10:2310:23, 1 March 2022‎ Sara Zand talk contribs‎ 12,348 bytes +3‎ →‎The diagnosis of heart failure with mildly reduced ejection fraction
• curprev 10:1610:16, 1 March 2022‎ Sara Zand talk contribs‎ 12,345 bytes +459‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 10:1010:10, 1 March 2022‎ Sara Zand talk contribs‎ 11,886 bytes +440‎ →‎Angiotensin receptor II type 1 receptor blockers
• curprev 10:0510:05, 1 March 2022‎ Sara Zand talk contribs‎ 11,446 bytes +421‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 08:2908:29, 1 March 2022‎ Sara Zand talk contribs‎ 11,025 bytes +286‎ →‎Heart failure preserved ejection fraction (HFpEF)
• curprev 07:5907:59, 1 March 2022‎ Sara Zand talk contribs‎ 10,739 bytes +32‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 07:5507:55, 1 March 2022‎ Sara Zand talk contribs‎ 10,707 bytes +2‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 07:5407:54, 1 March 2022‎ Sara Zand talk contribs‎ 10,705 bytes +2‎ →‎Beta-blockers
• curprev 07:5307:53, 1 March 2022‎ Sara Zand talk contribs‎ 10,703 bytes +15‎ No edit summary
• curprev 07:5207:52, 1 March 2022‎ Sara Zand talk contribs‎ 10,688 bytes −6,236‎ →‎Medications
• curprev 07:5207:52, 1 March 2022‎ Sara Zand talk contribs‎ 16,924 bytes −630‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 07:0507:05, 1 March 2022‎ Sara Zand talk contribs‎ 17,554 bytes −3,224‎ →‎The diagnosis of heart failure preserved ejection fraction
• curprev 06:2806:28, 1 March 2022‎ Sara Zand talk contribs‎ 20,778 bytes −11,174‎ →‎Heart failure preserved ejection fraction]] (HFpEF
• curprev 05:4805:48, 1 March 2022‎ Sara Zand talk contribs‎ 31,952 bytes +11,588‎ →‎Medications indicated in patients with New York Heart Association (NYHA class II–IV) HFmrEF (heart failure with mildly reduced ejection fraction) (LVEF41-49%)
• curprev 05:3705:37, 1 March 2022‎ Sara Zand talk contribs‎ 20,364 bytes +1‎ →‎Heart failure mildly reduced ejection fraction (EF (41-49%) (HPmrEF)
• curprev 05:3705:37, 1 March 2022‎ Sara Zand talk contribs‎ 20,363 bytes +19‎ →‎Heart failure mildly reduced ejection fraction HPmrEF
• curprev 05:3205:32, 1 March 2022‎ Sara Zand talk contribs‎ 20,344 bytes 0‎ →‎Heart failure mildly reduced ejection fraction HPmEEF
• curprev 05:3105:31, 1 March 2022‎ Sara Zand talk contribs‎ 20,344 bytes +37‎ →‎HPmrEF and HFpEF
• curprev 05:3005:30, 1 March 2022‎ Sara Zand talk contribs‎ 20,307 bytes −659‎ →‎Devices
• curprev 05:2705:27, 1 March 2022‎ Sara Zand talk contribs‎ 20,966 bytes +1,145‎ →‎Angiotensin receptor-neprilysin inhibitor
• curprev 05:2005:20, 1 March 2022‎ Sara Zand talk contribs‎ 19,821 bytes +4‎ →‎Angiotensin receptor-neprilysin inhibitor
• curprev 05:2005:20, 1 March 2022‎ Sara Zand talk contribs‎ 19,817 bytes −1,141‎ →‎Beta-blockers
• curprev 05:0505:05, 1 March 2022‎ Sara Zand talk contribs‎ 20,958 bytes −27‎ →‎Angiotensin-converting enzyme inhibitors
• curprev 04:5604:56, 1 March 2022‎ Sara Zand talk contribs‎ 20,985 bytes +3,277‎ →‎Medications indicated in patients with New York Heart Association (NYHA class II–IV) HFmrEF (heart failure with mildly reduced ejection fraction) (LVEF41-49%)

11 February 2022

• curprev 10:2910:29, 11 February 2022‎ Sara Zand talk contribs‎ 17,708 bytes +4‎ →‎Medications indicated in patients with New York Heart Association (NYHA class II–IV) HFmrEF (heart failure with mildly reduced ejection fraction) (LVEF41-49%)
• curprev 10:2810:28, 11 February 2022‎ Sara Zand talk contribs‎ 17,704 bytes −10‎ →‎Medications indicated in patients with New York Heart Association (NYHA class II–IV) HFmrEF (heart failure with mildly reduced ejection fraction) (LVEF41-49%)
• curprev 10:2810:28, 11 February 2022‎ Sara Zand talk contribs‎ 17,714 bytes −392‎ →‎Medications indicated in patients with New York Heart Association (NYHA class II–IV) HFmrEF (heart failure with mildly reduced ejection fraction) (LVEF41-49%)
• curprev 10:1410:14, 11 February 2022‎ Sara Zand talk contribs‎ 18,106 bytes +5‎ →‎HFpEF pharmacotherapy
• curprev 10:1310:13, 11 February 2022‎ Sara Zand talk contribs‎ 18,101 bytes +1,998‎ →‎HFpEF pharmacotherapy
• curprev 09:5209:52, 11 February 2022‎ Sara Zand talk contribs‎ 16,103 bytes +2,520‎ →‎HFpEF pharmacotherapy
• curprev 09:2809:28, 11 February 2022‎ Sara Zand talk contribs‎ 13,583 bytes −7,205‎ /* 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure/2013 ACCF/AHA Guideline for the Management of Heart Failure.{{cite journal |vauthors=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL |title=2013 ACCF/AHA guideline for the manage...

29 July 2020

• curprev 21:0621:06, 29 July 2020‎ WikiBot talk contribs‎ m 20,788 bytes −27‎ Bot: Removing from Primary care

28 January 2020

• curprev 20:5920:59, 28 January 2020‎ Skazmi talk contribs‎ 20,815 bytes +110‎ No edit summary Tag: Visual edit

22 December 2017

• curprev 13:5213:52, 22 December 2017‎ Badgettrg talk contribs‎ 20,705 bytes +145‎ →‎Aldosterone Antagonists

1 May 2017

• curprev 19:0419:04, 1 May 2017‎ Mehdi Pahlavani talk contribs‎ 20,560 bytes +1,488‎ /* 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure/2013 ACCF/AHA Guideline for the Management of Heart Failure.{{cite journal |vauthors=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, F...
• curprev 18:5918:59, 1 May 2017‎ Mehdi Pahlavani talk contribs‎ 19,072 bytes +1,267‎ /* 2013 ACCF/AHA Guideline for the Management of Heart Failure.{{cite journal |vauthors=Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE,...

7 April 2017

• curprev 13:5613:56, 7 April 2017‎ Mehdi Pahlavani talk contribs‎ 17,805 bytes +58‎ No edit summary Tag: Visual edit

15 November 2016

• curprev 14:4614:46, 15 November 2016‎ Mehdi Pahlavani talk contribs‎ 17,747 bytes +762‎ →‎HFpEF pharmacotherapy

14 November 2016

• curprev 19:4119:41, 14 November 2016‎ Mehdi Pahlavani talk contribs‎ 16,985 bytes +748‎ →‎HFpEF pharmacotherapy
• curprev 19:4019:40, 14 November 2016‎ Mehdi Pahlavani talk contribs‎ 16,237 bytes −1‎ →‎HFpEF pharmacotherapy
• curprev 19:3919:39, 14 November 2016‎ Mehdi Pahlavani talk contribs‎ 16,238 bytes +212‎ →‎HFpEF pharmacotherapy Tag: Visual edit
• curprev 19:2719:27, 14 November 2016‎ Mehdi Pahlavani talk contribs‎ 16,026 bytes +1‎ →‎HFpEF pharmacotherapy